Table 3.
Summary of culture and molecular studies of colonic microbiome
| Study | Subject | Sample | Method | Patient group | Main finding | Country of study |
| Balsari et al 96 |
|
Faeces | Culture | IBS |
|
Italy |
| Si et al 98 |
|
Faeces | Culture | IBS |
|
China |
| Malinen et al 99 |
|
Faeces | qPCR | IBS |
|
Finland |
| IBS-D |
|
|||||
| IBS-C |
|
|||||
| Mättö et al 100 |
|
Faeces | CulturePCR-DGGE | IBS |
|
Finland |
| Maukonen et al 101 |
|
Faeces |
|
IBS |
|
Finland |
| IBS-C |
|
|||||
| Kassinen et al 102 |
|
Faeces |
|
IBS |
|
Finland |
| Rajilić-Stojanović103 |
|
Faeces | Microarray | IBS |
|
Finland |
| Kerckhoffs et al 104 |
|
|
|
IBS |
|
The Netherlands |
| Krogius-Kurikka et al 105 |
|
Faeces | GC-profiling + sequencing of 16S rRNA genes | IBS-D |
|
Finland |
| Lyra et al 106 |
|
Faeces | qPCR | IBS-D |
|
Finland |
| IBS-C |
|
|||||
| IBS-A |
|
|||||
| Tana et al 107 |
|
Faeces |
|
IBS |
|
Japan |
| Codling et al 108 |
|
|
PCR-DGGE | IBS |
|
Ireland |
| Carroll et al 28 |
|
|
|
IBS-D |
|
USA |
| Noor et al 109 |
|
Faeces | PCR-DGGE + sequencing of 16S rRNA genes | IBS |
|
UK |
| Malinen et al 110 |
|
Faeces | qPCR |
|
Finland | |
| Ponnusamy et al 111 |
|
Faeces | DGGE + qPCR of 16sRNA genes |
|
Korea | |
| Rinttila et al 112 |
|
Faeces | qPCR | IBS |
|
Finland |
| Saulnier et al 113 |
|
Faeces | 16s Metagenomic sequencing and DNA microarray | IBS |
|
USA |
| Rajilic-Stojanovic et al 114 |
|
Faeces | Phylogenetic 16S rRNA microarray and qPCR | IBS |
|
Finland |
| Carroll et al 115 |
|
FaecesColonic mucosa | T-RFLP fingerprinting of 16S rRNA - PCR | IBS-D | Diminished microbial biodiversity in faecal samples | USA |
| Parkes et al 116 |
|
Colonic mucosa |
|
IBS | Expansion of mucosa-associated microbiota; mainly bacteroides and clostridia; association with IBS subgroups and symptoms | UK |
| Jeffery et al 117 |
|
Faeces | Pyrosequencing 16SrRNA | Clustering of IBS patients—normal-like versus abnormal microbiota composition (increased ratio of Firmicutes to Bacteroidetes); association with symptom profile | Sweden |
n, number of randomised subjects.
B, Bifidobacterium; C, constipation; C, Clostridium; Cl, Clostridium; ctrls, controls; D, diarrhoea; DGGE, denaturing gradient gel electrophoresis; FISH, fluorescent in situ hybridisation; IBS, irritable bowel syndrome; L, Lactobacillus; qPCR, quantitative PCR;R, Ruminococcus; S, Staphylococcus; T-RFLP, terminal restriction fragment length polymorphism.